- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04707638
Neurophysiological Characteristics of Subthalamic Deep-brain Stimulation (STN-DBS)
January 31, 2021 updated by: Wuhan Union Hospital, China
Neurophysiological Characteristics of Subthalamic Deep-brain Stimulation (STN-DBS) Under General Anesthesia for Patients With Parkinson's Disease or Dystonia and Their Correlation With Prognosis
The intraoperative neuroelectrophysiological signals were collected from patients undergoing STN-DBS under general anesthesia in the Neurosurgery Department of Wuhan union Hospital, and their preoperative conditions and postoperative efficacy will be evaluated.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The intraoperative neuroelectrophysiological signals were collected from patients undergoing STN-DBS under general anesthesia in the Neurosurgery Department of Wuhan union Hospital, and their preoperative conditions and postoperative efficacy will be evaluated.
The intraoperative neuroelectrophysiological signals would be analyzed.
Study Type
Observational
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with Parkinson's disease or dystonia and STN-DBS in neurosurgery department of Wuhan Union Hospital.
Description
Inclusion Criteria:
- Patients underwentSTN-DBS in neurosurgery department of Wuhan Union Hospital.
- Patients with Parkinson's disease or dystonia.
Exclusion Criteria:
1.Patients without enough follow-up length.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Parkinson's disease or dystonia patients
Patients with Parkinson's disease or dystonia and underwent STN DBS under general anesthesia in neurosurgery department
|
No intervention used
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Unified Parkinson's Disease Rating Scale (UPDRS)
Time Frame: Two years postoperatively
|
UPDRS has four parts: part I (nonmotor experiences of daily living, total score=16); part II (patient motor experience of daily living, total score=52); part III (clinician motor examination, total score=56); part IV (complications, total score=23).
The total score of all the four parts is147.
Higher scores means a worse outcome.
|
Two years postoperatively
|
Burke Fahn Marsden's Dystonia Rating Scales(BFMDRS)
Time Frame: Two years postoperatively
|
BFMDRS has two parts: BFMDRS movement part (BFMDRS-M) and BFMDRS disability part (BFMDRS-D).
The total score of BFMDRS-M is 120 and the total score of BFMDRS-D is 30.
Higher scores means a worse outcome.
|
Two years postoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Fu Peng, PHD, Neurosurgery department of Wuhan Union Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tsai ST, Kuo CC, Chen TY, Chen SY. Neurophysiological comparisons of subthalamic deep-brain stimulation for Parkinson's disease between patients receiving general and local anesthesia. Ci Ji Yi Xue Za Zhi. 2016 Apr-Jun;28(2):63-67. doi: 10.1016/j.tcmj.2016.02.003. Epub 2016 Apr 10.
- Yamada K, Goto S, Kuratsu J, Matsuzaki K, Tamura T, Nagahiro S, Murase N, Shimazu H, Kaji R. Stereotactic surgery for subthalamic nucleus stimulation under general anesthesia: a retrospective evaluation of Japanese patients with Parkinson's disease. Parkinsonism Relat Disord. 2007 Mar;13(2):101-7. doi: 10.1016/j.parkreldis.2006.07.008. Epub 2006 Oct 19.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Anticipated)
January 11, 2023
Study Completion (Anticipated)
January 11, 2023
Study Registration Dates
First Submitted
January 11, 2021
First Submitted That Met QC Criteria
January 12, 2021
First Posted (Actual)
January 13, 2021
Study Record Updates
Last Update Posted (Actual)
February 3, 2021
Last Update Submitted That Met QC Criteria
January 31, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NS20201230
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on No intervention used
-
Lawson Health Research InstituteCompletedUveitis | Macular Edema | Retinal Vein Occlusion | Retinitis | Orbital Diseases | Optic Neuritis | Keratoconjunctivitis Sicca | Conjunctivitis | Blindness | Xerophthalmia | Papilledema | Iridocyclitis | Retinal Artery Occlusion | Amaurosis Fugax | Scleritis | Eye Hemorrhage | Chorioretinitis | Choroid Hemorrhage
-
ProgenaBiomeCompletedCovid19 | SARS-CoV2 Infection | COVID-19 Pneumonia | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | COVID-19 Acute Bronchitis | COVID-19 Lower Respiratory InfectionUnited States
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaCompletedObesity | Type2 DiabetesUnited States
-
Royal Brompton & Harefield NHS Foundation TrustRecruitingNeuromuscular Diseases | Neurologic DisorderUnited Kingdom
-
Duke UniversityJohn Templeton FoundationTerminatedCannabis Use | Drug Use | Development, InfantUnited States
-
Erasmus Medical CenterNot yet recruiting
-
Universiti Tunku Abdul RahmanCompletedUniversity StudentsMalaysia
-
Boston Scientific CorporationCompleted
-
Felix RatjenCompletedObservationalCanada